EBITDA: Income before interest, taxes, depreciation and amortization.
CRISPR Therapeutics AG (CRSP) had EBITDA of $-447.31M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$37.31M |
|
$-366.25M |
|
-- |
|
$37.31M |
|
$503.88M |
|
$-466.57M |
|
$103.90M |
|
$-362.67M |
|
$-362.67M |
|
$-366.25M |
|
$-366.25M |
|
$-366.25M |
|
$-366.25M |
|
$-466.57M |
|
|
EBITDA |
$-447.31M |
84.36M |
|
84.36M |
|
$-4.34 |
|
$-4.34 |
|
| Balance Sheet Financials | |
$1.94B |
|
$134.09M |
|
$304.90M |
|
$2.24B |
|
$87.78M |
|
-- |
|
$222.17M |
|
$309.95M |
|
$1.93B |
|
$1.93B |
|
$1.93B |
|
85.74M |
|
| Cash Flow Statement Financials | |
$-142.77M |
|
$-280.48M |
|
$331.98M |
|
$401.07M |
|
$309.78M |
|
$-91.29M |
|
$86.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
22.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1250.38% |
|
-1250.38% |
|
-1198.77% |
|
-971.93% |
|
-981.54% |
|
$-144.68M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
1.49 |
|
244.55 |
|
-18.96% |
|
-18.96% |
|
-16.34% |
|
-18.96% |
|
$22.53 |
|
$-1.72 |
|
$-1.69 |
|